The GSK3β-USP22-LSD1 axis was validated in a cohort of clinical specimens from Grade IV GBM patients, where all three proteins showed increased levels of nuclear expression, significantly higher than their levels in a set of low-grade astrocytomas [98]. This evidence concerns the gene USP22 and glioblastoma.